In this regard, combination treatment with FAS enzyme inhibition associated with standard chemotherapy for the treatment of ovarian cancer resulted in a successful therapy approach both in in vitro and in vivo settings for therapy-resistant ovarian cancer cells [152,153]. Here, FAS is linked to ovarian cancer.